Israel - Hebrew - Ministry of Health

kamada ltd, israel - albumin human - תמיסה לאינפוזיה - albumin human 200 mg/ml - albumin - albumin - for restoration and maintenance of circulation blood volume where volume deficiency has been demonstrated and use of a colloid, is appropriate.the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

Israel - Hebrew - Ministry of Health

medigal ltd - albumin human 40 mg/ml - solution for injection - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations.

Israel - Hebrew - Ministry of Health

medigal ltd - albumin human 200 mg/ml - solution for injection - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demontrated, and use of a colloid, such as albumin, is appropriate.the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendations.

Israel - Hebrew - Ministry of Health

kamada ltd, israel - albumin human - תמיסה לאינפוזיה - albumin human 200 mg/ml - albumin - albumin - for restoration and maintenance of circulating blood volume where volume deficiency has been demontrated and use of a colloid such as albumin is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient based on official recommendations.

Israel - Hebrew - Ministry of Health

dover medical & scientific equipment ltd, israel - albumin human; plasma protein fraction - תמיסה לאינפוזיה - albumin human 50 g / 1000 ml; plasma protein fraction 96 % - albumin - albumin - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate.the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on the official recommendations

Israel - Hebrew - Ministry of Health

omrix biopharmaceuticals ltd, israel - calcium chloride; protein clottable; thrombin - תמיסה - thrombin 800 - 1200 iu / 1 ml; calcium chloride 5.6 - 6.20 mg / 1 ml; protein clottable 50 - 90 mg / 1 ml - combinations - combinations - general haemostasis : evicel is used as supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis. efficacy has been demonstrated in liver surgery and orthopaedic surgery.

Israel - Hebrew - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 20 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

Israel - Hebrew - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - ezetimibe 10 mg; simvastatin 20 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

Israel - Hebrew - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - simvastatin 40 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

Israel - Hebrew - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - טבליה - ezetimibe 10 mg; simvastatin 40 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).